Publications

8 résultats Voir en premier : les plus pertinents | les plus récents
    • Politique internationale, Santé mentale, Maladies
    • 2012
    • Rapport
    • Anglais

    [la démence: une priorité de santé publique]
    The report “Dementia: a public health priority” has been jointly developed by WHO and Alzheimer's Disease International. The purpose of this report is to raise awareness of dementia as a public health priority, to articulate a public health approach and to advocate for action at international and national levels.
    Dementia is a syndrome that affects memory, thinking, behaviour and ability to perform everyday activities. The number of people living with dementia worldwide is currently estimated at 35.6 million. This number will double by 2030 and more than triple by 2050. Dementia is overwhelming not only for the people who have it, but also for their caregivers and families. There is lack of awareness and understanding of dementia in most countries, resulting in stigmatization, barriers to diagnosis and care, and impacting caregivers, families and societies physically, psychologically and economically.
    The report is expected to facilitate governments, policy-makers, and other stakeholders to address the impact of dementia as an increasing threat to global health. It is hoped that the report will promote dementia as a public health and social care priority worldwide.

    • Date de parution:
    • Editeur: Alzheimer’s Disease International (ADI) Organisation Mondiale de la Santé (OMS) [World Health Organization (WHO)]
    • Hygiène, Maladies, Statistiques
    • 2012
    • Rapport
    • Anglais

    The HAI-Net protocol for surveillance of surgical site infections in European hospitals. The main objective of this protocol is to ensure standardisation of definitions, of data collection and of reporting procedures for hospitals participating in the national/regional surveillance of surgical site infections SSI across Europe.

    • Date de parution:
    • Editeur: European Centre for Disease prevention and Control (ECDC)
    • Maladies, Politique internationale
    • 2012
    • Rapport
    • Anglais

    Chronic, non-communicable diseases are a challenge of epidemic proportions. At a global scale, non-communicable diseases are estimated to cost $47 trillion by 2030. Europe currently has the highest number of deaths and disability in the world due to these diseases.
    This paper represents the European Chronic Disease Alliance’s (ECDA) collective input to policy makers in the frame of the European Union’s reflection process on chronic disease, specifically called for in the Council conclusions of 7 December 2010 on “Innovative approaches for chronic diseases in public health and health care systems”. The ECDA would like to urge the European Commission and the Member States to include the recommendations provided herewith in any forthcoming strategy on chronic diseases.
    For the purpose of this paper, the ECDA definition for “chronic diseases” is: Chronic non-communicable disease or conditions that are of long duration and generally slow progression, linked by common risk factors such as tobacco, physical inactivity, nutrition, alcohol, environment, and are largely preventable.
    On the basis of these Council conclusions, this paper recommends a number of concrete measures that can be taken by the European Commission and Member States to tackle chronic diseases effectively. First and foremost the ECDA calls for a coordinated EU-led strategy to tackle the enormous challenge to societies posed by chronic diseases.

    • Date de parution:
    • Editeur: European Chronic Disease Alliance's (ECDA)
    • Maladies, Statistiques
    • 2012
    • Rapport
    • Anglais

    [Statistiques européennes de maladies cardiovasculaires 2012]
    This is the fourth edition of European Cardiovascular Disease Statistics. This fourth edition is published jointly by the European Heart Network, the European Society of Cardiology and the British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford. It is part of the European Heart Health Strategy II (EuroHeart II) project and benefits from co-funding from the European Union in the framework of the health programme. CVD remains the main cause of death in Europe with very significant differences in mortality rates between countries.
    The differences are greatest between Northern, Southern and Western European countries and Central and Eastern European Countries. There are also differences between Western and Southern European countries with Southern European countries still having lower death rates from CVD than Western European countries. However, policy makers need to consider the differences and take a close look at risk factor prevalence and trends. Differences between Southern and Western European countries may persist but they are narrowing. This may be good news for Western Europe not necessarily for Southern Europe.
    The data presented in the fourth edition of European Cardiovascular Disease Statistics show that our efforts to reduce mortality from cardiovascular diseases have been successful. Most noticeably, following steep increases in CVD mortality in some Central and Eastern European countries, these countries are now since the mid-2000 experiencing a decrease. However, the cost to the European Union economies of cardiovascular diseases (CVD) is not decreasing.
    A read through the chapters of the European Cardiovascular Disease Statistics confirms that Europe suffers badly from lack of data and, particularly, lack of comparable data. This is true for prevalence and incidence rates, rates of surgical procedures as well as for diets. The European Union has an important task in developing standard methods for collecting information or agreed procedures for calibration of locally appropriate methods and questionnaires, to ensure effective service planning and quality of care for patients across the European Union.

    • Date de parution:
    • Editeur: European Heart Network (EHN)
    • Maladies, Santé sexuelle, Statistiques
    • 2012
    • Rapport
    • Anglais

    [Indice européen de performance pour la lutte contre l'hépatite]
    Chaque année, les troubles hépatiques causent 125.000 décès en Europe, où quelques 23 millions de personnes sont atteintes, le plus souvent sans le savoir, d'une forme d'hépatite. Ces personnes constituent par conséquent un facteur de risque élevé eu égard à la propagation de cette infection. Une nouvelle étude vient d'être menée afin de comparer les traitements et les politiques de lutte contre l'hépatite dans 30 pays européens, et ainsi identifier les approches les plus efficaces afin d'élaborer une méthodologie de référence à l'échelle paneuropéenne pour la lutte contre l'hépatite. La France arrive en tête, suivie de la Slovénie et de l'Allemagne. Le Luxembourg se classe 19e, avec 663 points sur 1.000.

    • Date de parution:
    • Editeur: Health Consumer Powerhouse
    • Politique internationale, Maladies
    • 2012
    • Rapport
    • Anglais

    [Rapport 2012 sur l’état de l’art des activités relatives aux maladies rares en Europe - Partie I: Aperçu des activités sur les maladies rares en Europe ]
    This document was produced by the Scientific Secretariat of the European Union Committee of Experts on Rare Diseases (EUCERD), through the EUCERD Joint Action: Working for Rare Diseases (N° 2011 22 01), which covers a three year period (March 2012 – February 2015).
    The present report aims to provide an informative and descriptive overview of rare disease activities at European Union (EU) and Member State (MS) level in the field of rare diseases and orphan medicinal products up to the end of 2011. A range of stakeholders in each Member State/country have been consulted during the elaboration of the report, which has been validated as an accurate representation of activities at national level, to the best of their knowledge, by the Member State/country representatives of the European Union Committee of Experts on Rare Diseases. The reader, however, should bear in mind that the information provided is not exhaustive and is not an official position of either the European Commission, its Agencies or national health authorities.
    The report is split into five parts available on the EURCED website

    • Part I: Overview of rare disease activities in Europe
    • Part II: Key developments in the field of rare diseases in 2011
    • Part III: European Commission activities in the field of rare diseases
    • Part IV: European Medicines Agency activities and other European activities in the field of rare diseases
    • Part V: Activities in EU Member States and other European countries in the field of rare diseases
    Each part contains the following description of the methodology, sources and validation process of the entire report, and concludes with a selected bibliography and list of persons having contributed to the report.

    • Date de parution:
    • Editeur: European Union Committee of Experts on Rare Diseases (EUCERD)
    • Statistiques, Santé mentale, Maladies
    • 2012
    • Rapport
    • Anglais

    [L'Indice Européen des Maux de Tête 2012]
    As many as 50 million Europeans suffer from headache and migraine, for many with handicapping effects. Compared to other large diseases, there lacks outcomes data to tell what are the best therapies and if prevention matters. The first Euro Headache Index (EHI) compares in what way 29 European countries address and take care of headache and migraine, by healthcare and other measures. The Netherlands comes out number 1 on good headache environment, followed by Germany, Denmark and Austria.
    The 2012 EHI looks into the following areas: Patients rights and information, Professional awareness and education, Access to healthcare, Medication/treatment and Prevention. In total there are 34 indicators for measurement.

    • Date de parution:
    • Editeur: Health Consumer Powerhouse
  • Dernière modification le 12-10-2015